Tom Thurén

20.2k citations

58 papers · 4.5k indexed · 3 hit papers · h-index 29

Impact in

Immunology top 2%
- Atherosclerosis and Cardiovascular Diseases
Cardiology and Cardiovascular Medicine top 2%
- Cardiac Fibrosis and Remodeling

Papers in ⓘ

Biochemistry 14
- Lipid metabolism and biosynthesis 13
Endocrinology, Diabetes and Metabolism 11
- Diabetes, Cardiovascular Risks, and Lipoproteins 6

Co-authors: Paul M. Ridker (15 shared papers)Peter Libby (11 shared papers)Robert J. Glynn (7 shared papers)Jean MacFadyen (8 shared papers)Andrew Zalewski (1 shared paper)Giulia Renda (4 shared papers)Campbell P. Howard (6 shared papers)Jorma A. Virtanen (12 shared papers)
Journals: Biochemistry (7 papers)Chemistry and Physics of Lipids (5 papers)Journal of Biological Chemistry (4 papers)European Heart Journal (4 papers)Journal of the American College of Cardiology (4 papers)
Partner nations: United States Finland Switzerland

In The Last Decade

Tom Thurén

58 papers receiving 4.4k citations

Hit Papers

align trajectories log scale

Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure 2019 · 458 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2019 Circulation
2018 European Heart Journal
2011 American Heart Journal

Peers

Countries citing papers authored by Tom Thurén

Since Specialization

Citations

This map shows the geographic impact of Tom Thurén's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Thurén with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Thurén more than expected).

Fields of papers citing papers by Tom Thurén

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom Thurén. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Thurén. The network helps show where Tom Thurén may publish in the future.

Co-authors

The 25 scholars most cited alongside Tom Thurén, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tom Thurén Line = papers co-authored together Tom Thurén links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 58 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) American Heart Journal ·Paul M. Ridker, Tom Thurén, Andrew Zalewski, Peter Libby Hit paper breakdown →	2011	609
2	Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure Circulation ·Brendan M. Everett, Jan H. Cornel, Mitja Lainščak, Stefan D. Anker, Antonio Abbate, Tom Thurén, Peter Libby, Robert J. Glynn, Paul M. Ridker Hit paper breakdown →	2019	458
3	Effects of Interleukin-1β Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen Circulation ·Paul M. Ridker, Campbell P. Howard, Verena Walter, Giulia Renda, Peter Libby, Johannes Hensen, Tom Thurén	2012	430
4	Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) European Heart Journal ·Paul M. Ridker, Peter Libby, Jean MacFadyen, Tom Thurén, Christie M. Ballantyne, Francisco Antônio Helfenstein Fonseca, Wolfgang Köenig, Hiroaki Shimokawa, Giulia Renda, Robert J. Glynn Hit paper breakdown →	2018	395
5	Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes Journal of the American College of Cardiology ·Giulia Renda, Marc Y. Donath, Aruna D. Pradhan, Tom Thurén, Prem Pais, José Carlos Nicolau, Robert J. Glynn, Peter Libby, Paul M. Ridker	2018	248
6	Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease Journal of the American College of Cardiology ·Paul M. Ridker, Jean MacFadyen, Robert J. Glynn, Wolfgang Köenig, Peter Libby, Giulia Renda, Martin Lefkowitz, Tom Thurén, Jan H. Cornel	2018	206
7	Increased plasma phospholipase-A2 activity in schizophrenic patients: Reduction after neuroleptic therapy Biological Psychiatry ·Wagner F. Gattaz, Manfred Köllisch, Tom Thurén, Jorma A. Virtanen, Paavo K.J. Kinnunen	1987	177
8	Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis European Heart Journal ·Paul M. Ridker, Jean MacFadyen, Tom Thurén, Peter Libby	2019	162
9	Increased serum phospholipase A2 activity in schizophrenia: a replication study. PubMed ·Gattaz Wf, Hübner Cv, Nevalainen Tj, Tom Thurén, Kinnunen Pk	1990	152
10	Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial Journal of the American College of Cardiology ·Brendan M. Everett, Jean MacFadyen, Tom Thurén, Peter Libby, Robert J. Glynn, Paul M. Ridker	2020	139
11	Effects of Interleukin-1β Inhibition on Incident Hip and Knee Replacement Annals of Internal Medicine ·Matthias Schieker, Philip G. Conaghan, Linda Mindeholm, Jens Præstgaard, Daniel H. Solomon, Celeste Scotti, Herman Gram, Tom Thurén, Ronenn Roubenoff, Paul M. Ridker	2020	108
12	Effect of anti‐ IL ‐1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo‐controlled trial Diabetes Obesity and Metabolism ·A Rissanen, Campbell P. Howard, Jaco Botha, Tom Thurén, (unknown)	2012	107
13	Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: Results of secondary endpoints from a randomized, placebo-controlled trial Diabetes & Metabolism ·J. Hensen, Campbell P. Howard, Verena Walter, Tom Thurén	2013	91
14	Effects of Interleukin-1β Inhibition on Blood Pressure, Incident Hypertension, and Residual Inflammatory Risk Hypertension ·Alexander Rothman, Jean MacFadyen, Tom Thurén, Alastair J.S. Webb, David G. Harrison, Tomasz J. Guzik, Peter Libby, Robert J. Glynn, Paul M. Ridker	2019	88
15	Hepatic lipase and HDL metabolism Current Opinion in Lipidology ·Tom Thurén	2000	86
16	Relationship of Interleukin-1β Blockade With Incident Gout and Serum Uric Acid Levels Annals of Internal Medicine ·Daniel H. Solomon, Robert J. Glynn, Jean MacFadyen, Peter Libby, Tom Thurén, Brendan M. Everett, Paul M. Ridker	2018	80
17	Hepatic lipase hydrolysis of lipid monolayers. Regulation by apolipoproteins. Journal of Biological Chemistry ·Tom Thurén, Rebecca W. Wilcox, Patricia Sisson, Moseley Waite	1991	63
18	Role of apolipoprotein E in hepatic lipase-catalyzed hydrolysis of phospholipid in high-density lipoproteins Biochemistry ·Tom Thurén, Karl H. Weisgraber, Patricia Sisson, Moseley Waite	1992	61
19	Evidence for the control of the action of phospholipases A by the physical state of the substrate Biochemistry ·Tom Thurén, Petri J. Vainío, Jorma A. Virtanen, Pentti Somerharju, Kurt Blomqvist, Paavo K.J. Kinnunen	1984	61
20	Triggering of the activity of phospholipase A2 by an electric field Biochemistry ·Tom Thurén, Antti Pekka Tulkki, Jorma A. Virtanen, Paavo K.J. Kinnunen	1987	55

About Tom Thurén

Tom Thurén is a scholar working on Biochemistry, Endocrinology, Diabetes and Metabolism, Clinical Biochemistry, Cell Biology and Immunology, having authored 58 papers that have together received 4.5k indexed citations. Recurring topics across this work include Lipid metabolism and biosynthesis (13 papers), Inflammasome and immune disorders (10 papers), Lipid Membrane Structure and Behavior (8 papers), Atherosclerosis and Cardiovascular Diseases (6 papers), Pancreatic function and diabetes (6 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (6 papers), Liver Disease Diagnosis and Treatment (5 papers) and Lipoproteins and Cardiovascular Health (5 papers). The work is most often cited by research in Immunology (1.2k citations), Cardiology and Cardiovascular Medicine (990 citations), Endocrinology, Diabetes and Metabolism (609 citations), Biological Psychiatry (87 citations) and Nephrology (236 citations). Tom Thurén has collaborated with scholars based in United States, Finland and Switzerland. Frequent co-authors include Paul M. Ridker, Peter Libby, Robert J. Glynn, Jean MacFadyen, Andrew Zalewski, Giulia Renda, Campbell P. Howard, Jorma A. Virtanen, Paavo K.J. Kinnunen and Verena Walter. Their work appears in journals such as Biochemistry, Chemistry and Physics of Lipids, Journal of Biological Chemistry, European Heart Journal and Journal of the American College of Cardiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact